Navigation Links
Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units
Date:11/10/2008

daily applications for up to 20 weeks. The MATRIX Phase 2b clinical trial is evaluating the safety and efficacy of Excellarate for the potential treatment of non-healing diabetic foot ulcers and is expected to enroll up to approximately 210 patients at up to 30 U.S. sites. The Company expects to provide selected top-line data from the MATRIX study in the first quarter 2009.

Consistent with Cardium's overall business strategy and concurrent with the conduct of the MATRIX clinical trial, the Company expects to pursue strategic discussions with respect to potential development, marketing and sales partnerships for Excellarate. With continued clinical advancement, Excellarate offers the potential to be commercially available in late 2011 or early 2012.

Cardium Biologics, Inc.

Cardium's Generx(TM) product candidate (alferminogene tadenovec, Ad5FGF-4) is a DNA-based growth factor therapeutic being developed for potential use by interventional cardiologists as a one-time treatment to promote and stimulate the growth of collateral circulation in the hearts of patients with ischemic conditions such as recurrent angina. The current focus of Cardium's biologics program is to advance the Excellarate product candidate though its current Phase 2b MATRIX study. Following the near-term completion of enrollment in the MATRIX study, Cardium expects to be in a position to devote additional resources toward the Generx program, including a potentially reformulated composition that would allow the Generx study product to be stored under more convenient temperature conditions.

Cardium's pre-clinical research at Emory University for its product candidate, Corgentin(TM) (Ad5IGF-1), is continuing with the support of an NIH Small Business Innovation Research (SBIR) grant, to further establish the therapeutic potential of Corgentin to preserve heart tissue and cardiac function following a heart attack (acute myocardial infarction). Corgentin is a DNA therapeutic bas
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Cardium Announces FDA 510(K) Clearance of InnerCools RapidBlue(TM) Endovascular System
2. ITGI Medical Received a CE Mark for its Second Pericardium Covered Stent - AneuGraft(R) - for Tortuous Vessels
3. Cardium Announces InnerCools New RapidBlue(TM) System Obtains CE Mark for Commercial Sale in Europe and UL certification
4. Cardium Announces Follow-On Direct Investment by Institutional Investor
5. Cardium Selected for Inclusion in Russell Microcap Index
6. Cardiums InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems
7. Cardium Launches New AWARE Clinical Study Website
8. Over and Under(R) Pericardium Covered Stent is now in use in England and Proves Great Deliverability
9. Cardium Therapeutics Announces Annual Meeting of Stockholders to be Held June 5, 2008
10. Cardium Reports on First Quarter 2008 Highlights and Financial Results
11. Richard A. Schatz, M.D. Joins Cardiums Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... March 2, 2015 VG Life Sciences, ... for autoimmune and infectious diseases, announced that the ... an important new composition of matter patent covering ... targeting of CLIP. U.S. Patent ... VG Life Sciences, VG1177, a synthetic peptide which ...
(Date:3/2/2015)... Global Stem Cells Group.com ... Shenzhen HANK Bioengineering Co., Ltd. and its Chinese-American ... establish a stem cells training course in the ... 2015. , Shenzhen HANK is a biotechnology company ... microbiologist and virologist, to integrate research, development, production, ...
(Date:3/1/2015)... London, UK (PRWEB) March 01, 2015 ... a partnership agreement for quality market research promotion ... and sell research reports worked out by DataGroup ... Department at Market Publishers Ltd, commented on the ... to have DataGroup Booksellers in our team of ...
(Date:2/27/2015)... February 27, 2015 Immunovaccine Inc. (“Immunovaccine” ... of a fraudulent press release disseminated this morning by ... from Immunovaccine. This press release states that Immunovaccine has ... The press release did not originate from Immunovaccine ... within the press release. Please note that all ...
Breaking Biology Technology:VG Life Sciences Granted Key Composition Of Matter Patent 2VG Life Sciences Granted Key Composition Of Matter Patent 3Global Stem Cells Group Announces Alliance with HANK Bioengineering Co., Ltd. in Shenzhen, China 2Global Stem Cells Group Announces Alliance with HANK Bioengineering Co., Ltd. in Shenzhen, China 3Market Publishers Ltd and DataGroup Booksellers Sign Partnership Agreement 2Market Publishers Ltd and DataGroup Booksellers Sign Partnership Agreement 3Immunovaccine Disclaims Hoax Press Release 2
... ... Arlington, VA, will discuss practical approaches to President Obama’s challenges to "find the needle ... ... to connect the dots” on the Christmas bomber in his recent address to the ...
... new antimalarial drugs after discovering the normal function of ... protein, which causes resistance to the front-line drug chloroquine. ... the malarial chloroquine-resistance factor. The study examined transporter ... cell. The genes for these proteins are present in ...
... SAN DIEGO, Jan. 11 BioMed Realty Trust, Inc. (NYSE: ... subsidiary, BioMed Realty, L.P., has completed its previously announced private ... The company also announced that the initial purchasers fully exercised ... in a total sale of $180 million in aggregate principal ...
Cached Biology Technology:NDIA's Biometrics Conference to Address Practical Approaches to the President's Challenge of 'Connecting the Dots' and Implementing $1B for New and Additional Security 2Discovery provides new drug targets for malaria cure 2BioMed Realty, L.P. Completes $180 Million Offering of 3.75% Exchangeable Senior Notes, Including Full Exercise of Initial Purchasers' Over-Allotment Option 2BioMed Realty, L.P. Completes $180 Million Offering of 3.75% Exchangeable Senior Notes, Including Full Exercise of Initial Purchasers' Over-Allotment Option 3
(Date:2/18/2015)... , Feb. 18, 2015  Cepheid (NASDAQ: ... at the following conferences, and invited investors to participate via ... Boston, MA Tuesday, March 3, 2015 at ... Conference, Orlando, FL Wednesday, March 4, ... Webcasts To access the live webcasts for these events, please ...
(Date:2/12/2015)... 12, 2015   MedNet Solutions , a ... study management systems, has recently bolstered its ... iMedNet as the eClinical ... and healthcare consultants.  Building on the Program,s existing ... and numerous co-marketing opportunities), MedNet,s new and improved ...
(Date:2/11/2015)... 11, 2015 According ... Control Market by Product (Cards and Readers, Biometrics, Controllers, ... Government, Industrial, Healthcare, Education) and By Geography - Global Forecast and ... the Access Control Market is expected to ... a CAGR of 10.6% between 2014 and ...
Breaking Biology News(10 mins):Cepheid to Webcast Upcoming Financial Presentations 2MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4
... CHAMPAIGN, lll. A protein that helps pack DNA ... gene activity, scientists report. The researchers found that the protein, ... the cellular workbenches on which all proteins are made. ... of Cell Biology . A human cell,s genetic material ...
... fishes in the ocean,s deepest reachesthe hadal zone, below 6000 ... numerous at such depths than experts had thought. The authors ... of BioScience , observed 10 to 20 snailfish congregating ... lander in the Japan Trench. The observation period lasted only ...
... atmospheric carbon dioxide levels rise, so does the pressure on ... citizens is that plants will absorb some of the extra ... For a few decades now, researchers have hypothesized about one ... the CO 2 they take up from the atmosphere. ...
Cached Biology News:Histone H1 regulates gene activity throughout the cell cycle 2Histone H1 regulates gene activity throughout the cell cycle 3Study suggests more fish than thought may thrive in the ocean's depths 2Nitrogen pollution alters global change scenarios from the ground up 2Nitrogen pollution alters global change scenarios from the ground up 3
... for 25 chips provides the chips and ... (at nanogram levels) with the Experion automated ... StdSens microfluidic chips, 2 x 1,250 microliters ... StdSens stain, 2 x 20 microliters RNA ...
...
... Accuri's C6 Flow Cytometer System is a full ... system including: the C6 Flow Cytometer, CFlow Software, ... C6 Flow Cytometer System provides all the capabilities ... fraction of the price. The C6 Flow Cytometer ...
Fingerprinting II Basic software is used for analyzing fingerprint sample types (electrophoretic gels, HPLC and other chromatographic patterns, spectrophotometric and densitometric curves)....
Biology Products: